PDCT-18 (LTBK-03). PHASE I CLINICAL TRIAL WITH ONCOLYTIC VIRUS DNX-2401 FOR DIPGS

Delta-24-RGD (DNX-2401 in the clinic) has been tested for adult glioblastoma presenting a safe profile and promising efficacy. Our group has showed that the virus is safe and effective in preclinical models of pHGG and DIPG. Moreover, we showed that the virus is able to trigger an antitumor immune r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Iñigo-Marco, Ignacio, Díez-Valle, Ricardo, Garcia-Moure, Marc, Patiño-García, Ana, González Huarriz, Marisol, Jones, Chris, Gomez-Manzano, Candelaria, Fueyo, Juan, Alonso, Marta M, Tejada, Sonia
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Late Breaking Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6873625/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz219.1197
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados